GameStop (NYSE: GME) announced that they will be reporting their fourth quarter and year-end financials after hours on March 23rd. Analysts have a consensus $14.64 12-month price target on the company, via a total of seven analysts, with four analysts having a hold rating and three analysts having a sell rating on the company. The street high comes in at a $36 price target, and the lowest target comes from Credit Suisse with a $3.50 price target.
Six analysts have revenue estimates for the fourth quarter. The mean between all 16 is $2.2 billion; this number has been revised downwards from $2.4 billion at the start of the year. The highest analyst esimate is currently $2.36 billion, while the lowest comes from Credit Suisse with a $2 billion estimate.
For the full year, the average revenue estimate between six analysts is currently $5.18 billion. This number has been revised downwards from $5.38 billion at the start of the year. The highest analyst estimate is currently $5.33 billion, while the lowest comes from Credit Suisse with a $5 billion estimate.
Onto EBITDA estimates, there are currently five analysts who have fourth-quarter EBITDA estimates. The mean is currently $143.27 million, with this number having been revised down from $184.78 million at the start of the year. Street high is a $177.40 million EBITDA estimate and the lowest being from Credit Suisse with a $102.8 million estimate.
For the full year, the current EBITDA mean across only two analysts is -$71.56 million. This number has been revised down from -$25.78 million, where it sat at the start of the year.
Analysts estimate that quarterly earnings per share will come in at $1.47, with this number being revised down from $1.70 at the start of the year. Street high is $2.08 and the lowest estimate is $1.18 for the quarter.
For the full year, the current earnings per share estimate mean across only two analysts is -$3.27, with this number having been revised down from -$3.03 at the start of the year.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
